Adherent cell obtained from peripheral blood‐derived or bone marrow‐derived mononuclear cells demonstrating low‐density lipoprotein (LDL) uptake and isolectin‐binding capacity. These cells may be used as a potential therapy for a variety of vascular diseases. The number of circulating endothelial progenitor cells is reduced in patients with cardiovascular disease and may be a surrogate marker for this disease risk.